Back to today’s briefing

Story perspectives

PharmaCyte Struggles While Coherus Thrives in Q1 2025

3/17/2025

32 5

Summary

Story summary

PharmaCyte Biotech faced a tough start to Q1 FY2025, reporting no revenue and a staggering net loss of $3.05 million, largely due to setbacks from FDA clinical holds on its pancreatic cancer treatment. In contrast, Coherus BioSciences celebrated a triumphant return to profitability, raking in $266.96 million and netting $28.51 million, thanks to savvy divestitures and successful product launches.

1 of 1

Story summary

PharmaCyte Biotech faced a tough start to Q1 FY2025, reporting no revenue and a staggering net loss of $3.05 million, largely due to setbacks from FDA clinical holds on its pancreatic cancer treatment. In contrast, Coherus BioSciences celebrated a triumphant return to profitability, raking in $266.96 million and netting $28.51 million, thanks to savvy divestitures and successful product launches.